知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

157 条记录 (耗时 0.024 秒)

    HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1
    92.
    发明申请
    HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1 有权
    白细胞介素-13受体ALPHA 1的高亲和力抗体拮抗剂

    公开(公告)号：US20140056915A1

    公开(公告)日：2014-02-27

    申请号：US14052791

    申请日：2013-10-14

    申请人： CSL Limited

    发明人： Andrew Donald Nash ,  Manuel Baca ,  Louis Jerry Fabri ,  Dennis Zaller ,  William R. Strohl ,  Zhiqiang An

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2866 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/43 ,  C12P21/005

    摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

    摘要翻译： 公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。 抗体分子在抑制IL-13Rα1介导的活性中是有效的，因此，在治疗与hIL-13Rα1活性相关的病症中使用所需的拮抗剂。 本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。 还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。

    Papillomavirus vaccine
    93.
    发明申请
    Papillomavirus vaccine 失效
    乳头瘤病毒疫苗

    公开(公告)号：US20040214331A1

    公开(公告)日：2004-10-28

    申请号：US10732345

    申请日：2003-12-11

    申请人： The Universtiy of Queensland and CSL Limited

    发明人： Ian Frazer ,  Jian Zhou

    IPC分类号： C12N015/86 ,  C12N007/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/5258 ,  C12N7/00 ,  C12N2710/20022 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2710/20043 ,  C12Q1/701 ,  Y10S977/802

    摘要： A method of providing papillomavirus like particles which may be used for diagnostic purposes or for incorporation in a vaccine for use in relation to infections causd by papillomavirus. The method includes an initial step of constructing one or more recombinant DNA molecules which each encode papillomavirus L1 protein or a combination of papillomavirus L1 protein and papillomavirus L2 protein followed by a further step of transfecting a suitable host cell with one or more of the recombinant DNA molecules so that virus like particles (VLPs) are produced within the cell after expression of the L1 or combination of L1 and L2 proteins. The VLPs are also claimed per se as well as vaccines incorporating the VLPs.

    摘要翻译： 提供乳头瘤病毒样颗粒的方法，其可用于诊断目的或用于结合用于与由乳头瘤病毒引起的感染有关的疫苗中。 该方法包括构建一个或多个重组DNA分子的初始步骤，每个重组DNA分子编码乳头瘤病毒L1蛋白或乳头瘤病毒L1蛋白和乳头瘤病毒L2蛋白的组合，接着进一步用一种或多种重组DNA转染合适的宿主细胞 分子，使得在表达L1或L1和L2蛋白的组合之后，在细胞内产生病毒样颗粒（VLP）。 本身还要求VLP以及结合VLP的疫苗。

    Method for improving the stability of purified Factor VIII after reconstitution
    95.
    发明授权
    Method for improving the stability of purified Factor VIII after reconstitution 有权

    公开(公告)号：US11510968B2

    公开(公告)日：2022-11-29

    申请号：US17109366

    申请日：2020-12-02

    申请人： CSL Limited

    发明人： Carsten Horn ,  Sabine Zollner ,  Hubert Metzner ,  Stefan Schulte

    IPC分类号： A61K38/00 ,  A61K38/37 ,  C07K14/755

    摘要： The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.

    METHOD FOR IMPROVING THE STABILITY OF PURIFIED FACTOR VIII AFTER RECONSTITUTION
    99.
    发明申请
    METHOD FOR IMPROVING THE STABILITY OF PURIFIED FACTOR VIII AFTER RECONSTITUTION 有权

    公开(公告)号：US20210308229A1

    公开(公告)日：2021-10-07

    申请号：US17109366

    申请日：2020-12-02

    申请人： CSL Limited

    发明人： Carsten HORN ,  Sabine ZOLLNER ,  Hubert METZNER ,  Stefan SCHULTE

    IPC分类号： A61K38/37 ,  C07K14/755

    摘要： The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.

    TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF
    100.
    发明申请
    TREATMENT EMPLOYING ANTI-IL-l3R ANTIBODY OR BINDING FRAGMENT THEREOF 有权

    公开(公告)号：US20210277131A1

    公开(公告)日：2021-09-09

    申请号：US17272243

    申请日：2020-03-26

    申请人： Aslan Pharmaceuticals PTE LTD ,  CSL LIMITED

    发明人： Alison WARD

    IPC分类号： C07K16/28 ,  A61P29/00

    摘要： The present disclosure provides a method of treatment comprising inhibiting IL-13R with an antibody or binding fragment thereof specific for the receptor with a VH sequence of SEQ ID NO: 51 or a sequence at least 95% identical thereto, and VL sequence of SEQ ID NO: 53 or a sequence at least 95% identical thereto, wherein said antibody or binding fragment is administered at a dose in the range 600 mg to 900 mg at least once each month, in particular less than twice a month.